Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(1.13)
# 3,639
Out of 4,457 analysts
124
Total ratings
38.2%
Success rate
-1.3%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $4 | $0.9206 | +334.50% | 1 | Jun 25, 2026 | |
| TENX Tenax Therapeutics | Maintained: Buy | $35 | $13.50 | +159.26% | 2 | Jun 24, 2026 | |
| INSM Insmed | Maintained: Buy | $230 → $235 | $104.74 | +124.37% | 3 | Jun 10, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $2.38 | +68.07% | 1 | May 21, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $4 | $1.93 | +107.25% | 2 | May 18, 2026 | |
| PTHS Pelthos Therapeutics | Initiated Coverage: Buy | $50 | $27.55 | +81.49% | 1 | Apr 1, 2026 | |
| CTMX CytomX Therapeutics | Maintained: Buy | $10 → $12 | $3.74 | +220.86% | 5 | Mar 20, 2026 | |
| GOSS Gossamer Bio | Downgraded: Hold | n/a | $0.164 | - | 6 | Mar 20, 2026 | |
| UTHR United Therapeutics | Initiated Coverage: Buy | $525 → $625 | $544.92 | +14.70% | 4 | Mar 12, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $85 | $57.67 | +47.39% | 18 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $6.14 | +79.15% | 5 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $450 → $400 | $293.52 | +36.28% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.24 | n/a | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $499.65 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $405 → $340 | $360.55 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $52 → $55 | $58.56 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $70 → $80 | $126.33 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $795 → $925 | $631.81 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $10 | $16.79 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.91 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $56.35 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $5.76 | n/a | 4 | Mar 20, 2023 |
Quince Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $0.9206
Upside: +334.50%
Tenax Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: $35
Current: $13.50
Upside: +159.26%
Insmed
Jun 10, 2026
Maintained: Buy
Price Target: $230 → $235
Current: $104.74
Upside: +124.37%
Connect Biopharma Holdings
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $2.38
Upside: +68.07%
Inhibikase Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $4
Current: $1.93
Upside: +107.25%
Pelthos Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $27.55
Upside: +81.49%
CytomX Therapeutics
Mar 20, 2026
Maintained: Buy
Price Target: $10 → $12
Current: $3.74
Upside: +220.86%
Gossamer Bio
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.164
Upside: -
United Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $525 → $625
Current: $544.92
Upside: +14.70%
BioMarin Pharmaceutical
Mar 2, 2026
Maintained: Buy
Price Target: $85
Current: $57.67
Upside: +47.39%
Feb 23, 2026
Maintained: Buy
Price Target: $11
Current: $6.14
Upside: +79.15%
Feb 12, 2026
Maintained: Hold
Price Target: $450 → $400
Current: $293.52
Upside: +36.28%
Mar 20, 2025
Maintained: Buy
Price Target: $9
Current: $4.24
Upside: n/a
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $499.65
Upside: n/a
Feb 5, 2025
Maintained: Buy
Price Target: $405 → $340
Current: $360.55
Upside: n/a
Feb 4, 2025
Maintained: Hold
Price Target: $52 → $55
Current: $58.56
Upside: n/a
Nov 6, 2024
Maintained: Hold
Price Target: $70 → $80
Current: $126.33
Upside: n/a
Apr 17, 2024
Maintained: Hold
Price Target: $795 → $925
Current: $631.81
Upside: n/a
Feb 23, 2024
Maintained: Buy
Price Target: $15 → $10
Current: $16.79
Upside: n/a
Nov 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $9.91
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $56.35
Upside: n/a
Mar 20, 2023
Maintained: Hold
Price Target: $3
Current: $5.76
Upside: n/a